ArticleFrontiers in oncology2020
Overexpressed Pseudogene
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 80 citations in OpenAlex.
- Functional roles and clinical implications of pseudogenes signatures as emerging biomarkers in cancer.Discover oncology · 2026Review
- Density of tertiary lymphoid structures predict clinical outcome in hepatoblastoma.Pediatric research · 2026Article
- Article
- Article
- Multiomics analysis and prognostic modeling reveal the molecular features and potential therapeutic targets of breast cancer brain metastasis.Clinical and experimental medicine · 2025Article
- Mutually reinforcing relationship between Sjögren's syndrome and lung adenocarcinoma: insights from Mendelian randomisation, single-cell, and transcriptomic analyses.Frontiers of medicine · 2025Article
- The cancer stem cells characteristics analysis of LGR5 + cells that influence lung cancer risk by using single cell RNA-seq analysis.Scientific reports · 2025Article
- Genomic landscape of cancer in racially and ethnically diverse populations.Nature reviews. Genetics · 2025Review
- Identification of a novel immune-related gene signature by single-cell and bulk sequencing for the prediction of the immune landscape and prognosis of breast cancer.Cancer cell international · 2024Article
- Integration of bioinformatics and cellular experiments unveils the role of SYT12 in gastric cancer.BMC cancer · 2024Article
- CELSR3 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Article
- Enhancing pathological complete response prediction in breast cancer: the role of dynamic characterization of DCE-MRI and its association with tumor heterogeneity.Breast cancer research : BCR · 2024Article
- Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms.BMC cancer · 2024Article
- APOB is a potential prognostic biomarker in hepatocellular carcinoma.Discover oncology · 2024Article
- LncRNAs-Regulated High Expression of LAMC2 Reveals a Prognostic and Immunological Value in Pancreatic Adenocarcinoma.Biochemical genetics · 2024Article
- NCPAD2 is a favorable predictor of prognostic and immunotherapeutic biomarker for multiple cancer types including lung cancer.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2024Article
- SLA2 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Article
- High expression of CCDC69 is correlated with immunotherapy response and protective effects on breast cancer.BMC cancer · 2023Article
- Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis.Scientific reports · 2023Article
- TRIM6: An Upregulated Biomarker with Prognostic Significance and Immune Correlations in Gliomas.Biomolecules · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have been successfully used for treating melanoma and non-small cell lung cancer. However, many patients with breast cancer (BC) show low response to ICIs due to the paucity of infiltrating immune cells. Pseudogenes, as a particular kind of long-chain noncoding RNA, play vital roles in tumorigenesis, but their potential roles in tumor immunology remain unclear. In this study that used data from online databases, the novel pseudogene
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.